NR4A1 and breast carcinoma: Only the BCIRG 006 trial, which randomized into 3 arms (AC→T vs AC→TH vs TCH arm) 3,222 women with HER2 positive breast cancer and included patients with node positive or high risk node negative disease (i.e. with at least one of the following risk factors: tumor size > 2 cm, histologic and/or nuclear grade 2–3, age < 35, hormone receptor negative status), enrolled 148 women with tumor size <1 cm [16].